At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
EVAX Evaxion Biotech A/S
Trading 01-13 12:00:42 EST
5.08
-0.10
-1.92%
High5.37Low5.05Vol9.13K
Open5.19D1 Closing5.18Amplitude6.04%
Mkt Cap42.18MTradable Cap28.11MTotal Shares8.30M
T/O47.00KT/O Rate0.17%Tradable Shares5.53M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Lake Street Sticks to Its Buy Rating for Evaxion Biotech (EVAX)
TIPRANKS  ·  01-13 22:16
Lake Street Sticks to Its Buy Rating for Evaxion Biotech (EVAX)
Evaxion A/S Announces Expansion of AI-Immunology™ Platform Into Autoimmune Diseases and Outlines 2026 Milestones Including Biomarker Data, Clinical Efficacy Results, and Pipeline Advancements
Reuters  ·  01-13 21:00
Evaxion A/S Announces Expansion of AI-Immunology™ Platform Into Autoimmune Diseases and Outlines 2026 Milestones Including Biomarker Data, Clinical Efficacy Results, and Pipeline Advancements
Evaxion A/S to Present 2026 Milestones at Biotech Showcase Conference
Reuters  ·  01-07
Evaxion A/S to Present 2026 Milestones at Biotech Showcase Conference
European Equities Traded in the US as American Depositary Receipts Little Changed in Friday Trading; Gains 2% for Week
MT Newswires Live  ·  2025-12-27
European Equities Traded in the US as American Depositary Receipts Little Changed in Friday Trading; Gains 2% for Week
BUZZ-U.S. STOCKS ON THE MOVE-Intuitive Machines, Palo Alto Networks, Redwire
Reuters  ·  2025-12-19
BUZZ-U.S. STOCKS ON THE MOVE-Intuitive Machines, Palo Alto Networks, Redwire
Evaxion a/S - Co Retains Global Rights to Evx-B2 and Will Look for Another Potential Licensing Partner
THOMSON REUTERS  ·  2025-12-19
Evaxion a/S - Co Retains Global Rights to Evx-B2 and Will Look for Another Potential Licensing Partner
Evaxion a/S - Msd Declines to Exercise Option for Evaxion's Gonorrhea Vaccine Candidate Evx-B2
THOMSON REUTERS  ·  2025-12-19
Evaxion a/S - Msd Declines to Exercise Option for Evaxion's Gonorrhea Vaccine Candidate Evx-B2
Evaxion a/S - No Impact on Evaxion's Cash Runway Extending to Second Half of 2027
THOMSON REUTERS  ·  2025-12-19
Evaxion a/S - No Impact on Evaxion's Cash Runway Extending to Second Half of 2027
Evaxion a/S - Eligible for up to $592 Mln in Milestone Payments Associated With the Development of Evx-B3
THOMSON REUTERS  ·  2025-12-19
Evaxion a/S - Eligible for up to $592 Mln in Milestone Payments Associated With the Development of Evx-B3
Evaxion Provides Update on Msd Collaboration - Retains Global Rights to Gonorrhea Vaccine Candidate Evx-B2
THOMSON REUTERS  ·  2025-12-19
Evaxion Provides Update on Msd Collaboration - Retains Global Rights to Gonorrhea Vaccine Candidate Evx-B2
Evaxion provides update on MSD collaboration - retains global rights to Gonorrhea vaccine candidate EVX-B2
GlobeNewswire  ·  2025-12-19
Evaxion provides update on MSD collaboration - retains global rights to Gonorrhea vaccine candidate EVX-B2
European Equities Traded in the US as American Depositary Receipts Open Week Higher in Monday Trading
MT Newswires Live  ·  2025-12-16
European Equities Traded in the US as American Depositary Receipts Open Week Higher in Monday Trading
European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading
MT Newswires Live  ·  2025-12-12
European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading
European Equities Traded in the US as American Depositary Receipts Trend Higher in Wednesday Trading
MT Newswires Live  ·  2025-12-11
European Equities Traded in the US as American Depositary Receipts Trend Higher in Wednesday Trading
European Equities Traded in the US as ADRs Little Changed in Monday Trading
MT Newswires Live  ·  2025-12-09
European Equities Traded in the US as ADRs Little Changed in Monday Trading
Evaxion Unveils Promising Preclinical Data for Off-the-Shelf AML Vaccine EVX-04
Reuters  ·  2025-12-08
Evaxion Unveils Promising Preclinical Data for Off-the-Shelf AML Vaccine EVX-04
Evaxion Unveils Promising Preclinical Data for AML Vaccine EVX-04 at ASH Meeting
Reuters  ·  2025-12-07
Evaxion Unveils Promising Preclinical Data for AML Vaccine EVX-04 at ASH Meeting
European Equities Traded in the US as American Depositary Receipts Surge in Wednesday Trading
MT Newswires Live  ·  2025-11-27
European Equities Traded in the US as American Depositary Receipts Surge in Wednesday Trading
European Equities Traded in the US as American Depositary Receipts Little Changed in Monday Trading
MT Newswires Live  ·  2025-11-25
European Equities Traded in the US as American Depositary Receipts Little Changed in Monday Trading
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Down 3% for Week
MT Newswires Live  ·  2025-11-22
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Down 3% for Week

Introduction

Company Name.
Evaxion Biotech A/S
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies for cancers, bacterial diseases, and viral infections. The company develops EVX-01, a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy that is in Phase IIa trial for adjuvant melanoma; and EVX-03, a DNA-based immunotherapy for the treatment of various cancers. Its programs also include EVX-B1, EVX-B2, and EVX-V1, which are vaccines that are in pre-clinical stage for the treatment of bacterial and viral diseases. The company was incorporated in 2008 and is headquartered in Hørsholm, Denmark.
Issue price:
--